Shares in Stratagene have fallen 23.3 percent over the past week, though the reason for the decline is unclear. The company's shares dropped 15.3 percent last Thursday alone — two days after it announced a settlement with Takara Bio related to PCR enzyme blends, and a day before molecular diagnostics partner Focus Diagnostics announced that it was being acquired by Quest Diagnostics (see Briefs).

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have an account?
Login Now.

With H3Africa, Charles Rotimi has been working to bolster the representation of African participants and African researchers in genomics, Newsweek reports.

NPR reports that government and private insurers are being slow to cover recently approved CAR-T cell therapies.

CNBC reports that there are thousands of genetic tests available for consumers to chose between.

In Nature this week: genomic analysis of ducks, whole-genome doubling among tumor samples, and more.